Fri, May 9, 10:59 AM (3 days ago)
**ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Financial Performance** **Revenue and Profit Margins:** - **Revenue:** $197,122,000, up 43.4% YoY. - **Operating Income:** $26,194,000, up 28.9% YoY. - **Net Income:** $15,681,000, down 13.3% YoY. - **EPS:** $0.70, down 16.7% YoY. **Cash Flow:** - **Operating Cash Flow:** $34,991,000, up 90.9% YoY. - **Investing Cash Flow:** -$19,846,000, down 320.5% YoY. - **Financing Cash Flow:** -$9,906,000, up 99.6% YoY. **Earnings Changes:** - **Revenue Growth:** Driven by Rare Disease (86.7% YoY) and Generics (40.5% YoY) segments. - **Operating Expenses:** Increased by 44.0% YoY, mainly due to SG&A (59.4% YoY) and Depreciation & Amortization (55.9% YoY). **Quarterly Performance:** - **Rare Disease:** Strong growth in Cortrophin Gel and new products ILUVIEN and YUTIQ. - **Generics:** Growth driven by new product launches and market share gains. - **Brands:** Slight decline due to volume decreases. **Trends and Uncertainties:** - **Positive Trends:** Growth in Rare Disease and Generics segments, new product launches. - **Uncertainties:** Competition, regulatory risks, and market volatility. **Future Operations Impact:** - **Growth Drivers:** Continued investment in Rare Disease, strategic acquisitions, and new product launches. - **Challenges:** Managing competition, regulatory compliance, and market access. **Key Metrics:** - **Gross Margin:** 37.1% (up from 35.8% YoY). - **Operating Margin:** 13.2% (down from 14.8% YoY). - **Net Margin:** 7.8% (down from 13.3% YoY). **Segment Performance:** - **Rare Disease and Brands:** $94,082,000 (up 50.3% YoY). - **Generics and Other:** $103,040,000 (up 37.7% YoY). **Cash and Debt:** - **Cash and Cash Equivalents:** $149,836,000 (up from $144,894,000 YoY). - **Debt:** $316,339,000 (up from $294,000,000 YoY). **Forward-Looking:** - **Guidance:** ANIP expects continued growth in Rare Disease and Generics segments, with potential challenges from competition and regulatory environment.